JP2020143066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020143066A5 JP2020143066A5 JP2020075470A JP2020075470A JP2020143066A5 JP 2020143066 A5 JP2020143066 A5 JP 2020143066A5 JP 2020075470 A JP2020075470 A JP 2020075470A JP 2020075470 A JP2020075470 A JP 2020075470A JP 2020143066 A5 JP2020143066 A5 JP 2020143066A5
- Authority
- JP
- Japan
- Prior art keywords
- absent
- aib
- glu
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 27
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 150000001720 carbohydrates Chemical class 0.000 claims 7
- 239000004094 surface-active agent Substances 0.000 claims 7
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 6
- 150000003431 steroids Chemical class 0.000 claims 5
- WNTGYJSOUMFZEP-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1C WNTGYJSOUMFZEP-UHFFFAOYSA-N 0.000 claims 3
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- -1 linker amino acid Chemical class 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108010087791 pyroglutamylhistidine Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- PPIIOFOWNPKGDP-IBEHDNSVSA-N (2R,3R,4S,5S,6R)-2-decyl-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound C(CCCCCCCCC)[C@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO PPIIOFOWNPKGDP-IBEHDNSVSA-N 0.000 claims 1
- QYICFPNWZRKTDX-QMCAAQAGSA-N (2R,3R,4S,5S,6R)-2-hexadecyl-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound C(CCCCCCCCCCCCCCC)[C@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO QYICFPNWZRKTDX-QMCAAQAGSA-N 0.000 claims 1
- KJFNPHUIPRFEEI-GNADVCDUSA-N (2R,3R,4S,5S,6R)-6-(hydroxymethyl)-2-octadecyloxane-2,3,4,5-tetrol Chemical compound C(CCCCCCCCCCCCCCCCC)[C@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO KJFNPHUIPRFEEI-GNADVCDUSA-N 0.000 claims 1
- NZRRQTWJVNMISZ-OUUBHVDSSA-N (2R,3R,4S,5S,6R)-6-(hydroxymethyl)-2-tetradecyloxane-2,3,4,5-tetrol Chemical compound C(CCCCCCCCCCCCC)[C@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO NZRRQTWJVNMISZ-OUUBHVDSSA-N 0.000 claims 1
- OOUZMUGHCDPALG-VZGLXOSZSA-N (2S,3S,4S,5R,6R)-3,4,5,6-tetrahydroxy-6-octadecyloxane-2-carboxylic acid Chemical compound C(CCCCCCCCCCCCCCCCC)[C@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)C(=O)O OOUZMUGHCDPALG-VZGLXOSZSA-N 0.000 claims 1
- ALYRJYOQVDSVBI-UYTYNIKBSA-N (2r,3r,4s,5s,6r)-2-dodecyl-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound CCCCCCCCCCCC[C@@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ALYRJYOQVDSVBI-UYTYNIKBSA-N 0.000 claims 1
- KITVZRVDBQNSDD-RKQHYHRCSA-N (2r,3r,4s,5s,6r)-6-(hydroxymethyl)-2-octyloxane-2,3,4,5-tetrol Chemical compound CCCCCCCC[C@@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KITVZRVDBQNSDD-RKQHYHRCSA-N 0.000 claims 1
- CLRWZDLKTLJVEF-ZXPJVPCYSA-N (2s,3s,4s,5r,6r)-3,4,5,6-tetrahydroxy-6-octyloxane-2-carboxylic acid Chemical compound CCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O CLRWZDLKTLJVEF-ZXPJVPCYSA-N 0.000 claims 1
- FCQMGQZEJINDNN-KVIJGQROSA-N (2s,3s,4s,5r,6r)-3,4,5,6-tetrahydroxy-6-tetradecyloxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O FCQMGQZEJINDNN-KVIJGQROSA-N 0.000 claims 1
- KZPCPTBVXOXXOY-GRYWWWGRSA-N (2s,3s,4s,5r,6r)-6-decyl-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O KZPCPTBVXOXXOY-GRYWWWGRSA-N 0.000 claims 1
- ZWSXIJDIJOZWHM-YIUJWAEMSA-N (2s,3s,4s,5r,6r)-6-hexadecyl-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZWSXIJDIJOZWHM-YIUJWAEMSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 238000007306 functionalization reaction Methods 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022127266A JP2022172128A (ja) | 2014-05-28 | 2022-08-09 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2024067692A JP2024102119A (ja) | 2014-05-28 | 2024-04-18 | インスリン抵抗性のための改善されたペプチド医薬品 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004156P | 2014-05-28 | 2014-05-28 | |
| US62/004,156 | 2014-05-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569787A Division JP6697807B2 (ja) | 2014-05-28 | 2015-05-28 | インスリン抵抗性のための改善されたペプチド医薬品 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127266A Division JP2022172128A (ja) | 2014-05-28 | 2022-08-09 | インスリン抵抗性のための改善されたペプチド医薬品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020143066A JP2020143066A (ja) | 2020-09-10 |
| JP2020143066A5 true JP2020143066A5 (enExample) | 2020-11-05 |
Family
ID=54699825
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569787A Active JP6697807B2 (ja) | 2014-05-28 | 2015-05-28 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2020075470A Pending JP2020143066A (ja) | 2014-05-28 | 2020-04-21 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2022127266A Pending JP2022172128A (ja) | 2014-05-28 | 2022-08-09 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2024067692A Pending JP2024102119A (ja) | 2014-05-28 | 2024-04-18 | インスリン抵抗性のための改善されたペプチド医薬品 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569787A Active JP6697807B2 (ja) | 2014-05-28 | 2015-05-28 | インスリン抵抗性のための改善されたペプチド医薬品 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127266A Pending JP2022172128A (ja) | 2014-05-28 | 2022-08-09 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2024067692A Pending JP2024102119A (ja) | 2014-05-28 | 2024-04-18 | インスリン抵抗性のための改善されたペプチド医薬品 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9856306B2 (enExample) |
| EP (2) | EP3155017B1 (enExample) |
| JP (4) | JP6697807B2 (enExample) |
| KR (3) | KR20250007694A (enExample) |
| CN (5) | CN117180445A (enExample) |
| AU (3) | AU2015266854B2 (enExample) |
| BR (1) | BR112016027595B1 (enExample) |
| CA (1) | CA2949701C (enExample) |
| DK (1) | DK3155017T3 (enExample) |
| ES (1) | ES2985732T3 (enExample) |
| FI (1) | FI3155017T3 (enExample) |
| HU (1) | HUE066179T2 (enExample) |
| IL (3) | IL285613B2 (enExample) |
| MX (2) | MX371033B (enExample) |
| NZ (2) | NZ757113A (enExample) |
| PL (1) | PL3155017T3 (enExample) |
| PT (1) | PT3155017T (enExample) |
| WO (1) | WO2015184177A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108892709A (zh) | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| US10471127B2 (en) | 2011-05-18 | 2019-11-12 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| KR102365582B1 (ko) | 2012-11-20 | 2022-02-18 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
| EP4047023A1 (en) * | 2012-11-20 | 2022-08-24 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CN117180445A (zh) | 2014-05-28 | 2023-12-08 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2019018350A1 (en) | 2017-07-17 | 2019-01-24 | Keith Roizman | TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES |
| CN111818971A (zh) | 2018-01-03 | 2020-10-23 | 梅德瑞斯糖尿病有限责任公司 | 用于治疗nash和其他紊乱的改进的肽药物 |
| WO2021168386A1 (en) * | 2020-02-21 | 2021-08-26 | Spitfire Pharma Llc | Glp-1r and gcgr agonists, formulations, and methods of use |
| US12171806B2 (en) | 2021-09-28 | 2024-12-24 | Spitfire Pharma Llc | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists |
| WO2022125598A1 (en) * | 2020-12-07 | 2022-06-16 | Spitfire Pharma Llc | Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists |
| CN113461747B (zh) * | 2021-07-12 | 2023-02-03 | 吉林化工学院 | 刺玫果中2个具有降血糖活性的化合物 |
| WO2024239961A1 (zh) * | 2023-05-24 | 2024-11-28 | 联邦生物科技(珠海横琴)有限公司 | 一种胰岛素衍生物及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
| US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
| AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
| US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
| US7776819B2 (en) | 2005-03-03 | 2010-08-17 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| JP2008539735A (ja) * | 2005-05-06 | 2008-11-20 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法 |
| WO2007002465A2 (en) | 2005-06-23 | 2007-01-04 | Rapid Pharmaceuticals, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| ES2397289T3 (es) | 2005-09-22 | 2013-03-06 | Biocompatibles Uk Ltd. | Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada |
| WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| EA017849B1 (ru) | 2007-02-15 | 2013-03-29 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соагонисты глюкагоновых/glp-1-рецепторов |
| PA8830501A1 (es) | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| PT2454282E (pt) | 2009-07-13 | 2015-06-23 | Zealand Pharma As | Análogos de glucagão acilados |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
| KR101453037B1 (ko) | 2011-03-23 | 2014-10-21 | 주식회사 엘지화학 | 전극조립체 및 이의 제조방법 |
| US10471127B2 (en) * | 2011-05-18 | 2019-11-12 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| CN108892709A (zh) | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| EP4047023A1 (en) * | 2012-11-20 | 2022-08-24 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| KR102365582B1 (ko) | 2012-11-20 | 2022-02-18 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
| RU2683039C2 (ru) * | 2013-04-18 | 2019-03-26 | Ново Нордиск А/С | Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения |
| CN117180445A (zh) | 2014-05-28 | 2023-12-08 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| MX382408B (es) * | 2014-10-24 | 2025-03-13 | Merck Sharp & Dohme Llc | Coagonistas de los receptores de glucagón y de glp-1. |
| CN111818971A (zh) * | 2018-01-03 | 2020-10-23 | 梅德瑞斯糖尿病有限责任公司 | 用于治疗nash和其他紊乱的改进的肽药物 |
-
2015
- 2015-05-28 CN CN202311098595.4A patent/CN117180445A/zh active Pending
- 2015-05-28 FI FIEP15798956.7T patent/FI3155017T3/fi active
- 2015-05-28 AU AU2015266854A patent/AU2015266854B2/en active Active
- 2015-05-28 CN CN202011222645.1A patent/CN113264994A/zh active Pending
- 2015-05-28 CN CN201910116865.7A patent/CN109865142A/zh active Pending
- 2015-05-28 KR KR1020247042894A patent/KR20250007694A/ko active Pending
- 2015-05-28 JP JP2016569787A patent/JP6697807B2/ja active Active
- 2015-05-28 CN CN202311098620.9A patent/CN117582516A/zh active Pending
- 2015-05-28 CN CN201580041790.0A patent/CN106661097A/zh active Pending
- 2015-05-28 PT PT157989567T patent/PT3155017T/pt unknown
- 2015-05-28 HU HUE15798956A patent/HUE066179T2/hu unknown
- 2015-05-28 DK DK15798956.7T patent/DK3155017T3/da active
- 2015-05-28 EP EP15798956.7A patent/EP3155017B1/en active Active
- 2015-05-28 KR KR1020237018945A patent/KR20230084337A/ko not_active Ceased
- 2015-05-28 NZ NZ757113A patent/NZ757113A/en unknown
- 2015-05-28 CA CA2949701A patent/CA2949701C/en active Active
- 2015-05-28 NZ NZ726623A patent/NZ726623A/en unknown
- 2015-05-28 KR KR1020167036463A patent/KR102542164B1/ko active Active
- 2015-05-28 ES ES15798956T patent/ES2985732T3/es active Active
- 2015-05-28 MX MX2016015594A patent/MX371033B/es active IP Right Grant
- 2015-05-28 EP EP24150928.0A patent/EP4397374A3/en active Pending
- 2015-05-28 IL IL285613A patent/IL285613B2/en unknown
- 2015-05-28 US US15/314,466 patent/US9856306B2/en active Active
- 2015-05-28 PL PL15798956.7T patent/PL3155017T3/pl unknown
- 2015-05-28 WO PCT/US2015/033042 patent/WO2015184177A1/en not_active Ceased
- 2015-05-28 MX MX2020000201A patent/MX384236B/es unknown
- 2015-05-28 BR BR112016027595-0A patent/BR112016027595B1/pt active IP Right Grant
-
2016
- 2016-11-17 IL IL249044A patent/IL249044B/en active IP Right Grant
-
2017
- 2017-11-21 US US15/820,127 patent/US10577405B2/en active Active
-
2020
- 2020-01-21 US US16/747,759 patent/US20200277351A1/en not_active Abandoned
- 2020-04-21 JP JP2020075470A patent/JP2020143066A/ja active Pending
- 2020-06-02 AU AU2020203609A patent/AU2020203609B2/en active Active
- 2020-06-21 IL IL275526A patent/IL275526B/en unknown
-
2022
- 2022-08-09 JP JP2022127266A patent/JP2022172128A/ja active Pending
-
2023
- 2023-02-08 AU AU2023200659A patent/AU2023200659A1/en active Pending
-
2024
- 2024-04-18 JP JP2024067692A patent/JP2024102119A/ja active Pending
- 2024-11-11 US US18/943,440 patent/US20250136656A1/en active Pending
- 2024-12-19 US US18/988,066 patent/US20250313604A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020143066A5 (enExample) | ||
| JP2020073481A5 (enExample) | ||
| JP2016501204A5 (enExample) | ||
| DE69601841T2 (de) | Camptothecinderivate | |
| DE69730332T2 (de) | Alkyldextran-polyalcohol Arzneimittel-Komplexe | |
| DE69434181T2 (de) | Therapeutische Peptidderivate | |
| JP5584236B2 (ja) | 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート | |
| FI94350B (fi) | Menetelmä T-soluavustaja-aktiivisuutta omaavien peptidien valmistamiseksi | |
| JP2014516037A5 (enExample) | ||
| DE69427650T2 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
| CN102702330B (zh) | 环状核心序列与生物素或穿膜肽相连而成的促黑激素类似物 | |
| DE69426206T2 (de) | Verbindungen mit wachstumshormonfreisetzenden eigenschaften | |
| JPH04506664A (ja) | 治療用ペプチド | |
| AU2009294871A1 (en) | Peptidomimetic macrocycles | |
| JPH04504406A (ja) | 治療用ペプチド | |
| JPS6218560B2 (enExample) | ||
| JPH0219397A (ja) | アルギニンバソプレシン拮抗剤の新規線形誘導体類 | |
| JPH08510260A (ja) | Ｌｈｒｈ拮抗剤 | |
| JP4805917B2 (ja) | 細胞分裂阻害剤として７位にて環状ペプチドと接合したカンプトテシン | |
| JP6562948B2 (ja) | 活性化ニューロテンシン分子及びその使用 | |
| JPH10501003A (ja) | 免疫調節作用を有する新規ペプチド | |
| DE69218200T2 (de) | Behandlung von leberkrebs | |
| US6828304B1 (en) | Peptides for treatment of cancer | |
| DE69403110T2 (de) | Zyklische Angiopeptin Derivate, deren Herstellung und pharmazeutische Zusammensetzungen | |
| JPS60237098A (ja) | アルギニンバソプレツシン拮抗薬の新規誘導体類 |